Therapeutic Area | MeSH |
---|---|
eye diseases | D005128 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ZIOPTAN | Thea Pharma | N-202514 RX | 2012-02-10 | 1 products, RLD, RS |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
open-angle glaucoma | EFO_0004190 | D005902 | H40.1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | 1 | 8 | 8 | 4 | 21 |
Ocular hypertension | D009798 | EFO_1001069 | H40.0 | 2 | 1 | 8 | 9 | 1 | 20 |
Glaucoma | D005901 | EFO_0000516 | H40 | 1 | 1 | 3 | 7 | 1 | 12 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | Tafluprost |
INN | tafluprost |
Description | Tafluprost (trade names Taflotan by Santen Pharmaceutical, Zioptan by Merck in the US and Saflutan by Mundipharma in Australia) is a prostaglandin analogue. It is used topically (as eye drops) to control the progression of open-angle glaucoma and in the management of ocular hypertension, alone or in combination with other medication. It reduces intraocular pressure by increasing the outflow of aqueous fluid from the eyes.
|
Classification | Small molecule |
Drug class | prostaglandins |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COc1ccccc1 |
PDB | — |
CAS-ID | 209860-87-7 |
RxCUI | — |
ChEMBL ID | CHEMBL1963683 |
ChEBI ID | 66899 |
PubChem CID | 6433101 |
DrugBank | DB08819 |
UNII ID | 1O6WQ6T7G3 (ChemIDplus, GSRS) |